229 related articles for article (PubMed ID: 32702530)
21. Lipid nanoparticle-based ribonucleoprotein delivery for in vivo genome editing.
Onuma H; Sato Y; Harashima H
J Control Release; 2023 Mar; 355():406-416. PubMed ID: 36773957
[TBL] [Abstract][Full Text] [Related]
22. PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy.
Choi JY; Ramasamy T; Kim SY; Kim J; Ku SK; Youn YS; Kim JR; Jeong JH; Choi HG; Yong CS; Kim JO
Acta Biomater; 2016 Jul; 39():94-105. PubMed ID: 27163403
[TBL] [Abstract][Full Text] [Related]
23. Engineered CRISPR Systems for Next Generation Gene Therapies.
Pineda M; Moghadam F; Ebrahimkhani MR; Kiani S
ACS Synth Biol; 2017 Sep; 6(9):1614-1626. PubMed ID: 28558198
[TBL] [Abstract][Full Text] [Related]
24. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
25. Controlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticles.
Yan Y; Fu J; Wang T; Lu X
Acta Biomater; 2017 Mar; 51():471-478. PubMed ID: 28131940
[TBL] [Abstract][Full Text] [Related]
26. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
27. Coassembly of nucleus-targeting gold nanoclusters with CRISPR/Cas9 for simultaneous bioimaging and therapeutic genome editing.
Tao Y; Yi K; Hu H; Shao D; Li M
J Mater Chem B; 2021 Jan; 9(1):94-100. PubMed ID: 33220661
[TBL] [Abstract][Full Text] [Related]
28. Delivery of CRISPR/Cas9 for therapeutic genome editing.
Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
[TBL] [Abstract][Full Text] [Related]
29. Biocompatible mesoporous silica-coated superparamagnetic manganese ferrite nanoparticles for targeted drug delivery and MR imaging applications.
Sahoo B; Devi KS; Dutta S; Maiti TK; Pramanik P; Dhara D
J Colloid Interface Sci; 2014 Oct; 431():31-41. PubMed ID: 24980623
[TBL] [Abstract][Full Text] [Related]
30. A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections.
Verma R; Sahu R; Singh DD; Egbo TE
Semin Cell Dev Biol; 2019 Dec; 96():44-52. PubMed ID: 30986568
[TBL] [Abstract][Full Text] [Related]
31. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
[TBL] [Abstract][Full Text] [Related]
32. Guiding mesenchymal stem cell differentiation using mesoporous silica nanoparticle-based films.
Andrée L; Barata D; Sutthavas P; Habibovic P; van Rijt S
Acta Biomater; 2019 Sep; 96():557-567. PubMed ID: 31284095
[TBL] [Abstract][Full Text] [Related]
33. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
[TBL] [Abstract][Full Text] [Related]
34. CRISPR/Cas9 Delivery Potentials in Alzheimer's Disease Management: A Mini Review.
Hanafy AS; Schoch S; Lamprecht A
Pharmaceutics; 2020 Aug; 12(9):. PubMed ID: 32854251
[TBL] [Abstract][Full Text] [Related]
35. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
36. Electrosprayed Alginate Nanoparticles as CRISPR Plasmid DNA Delivery Carrier: Preparation, Optimization, and Characterization.
Alallam B; Altahhan S; Taher M; Mohd Nasir MH; Doolaanea AA
Pharmaceuticals (Basel); 2020 Jul; 13(8):. PubMed ID: 32707857
[TBL] [Abstract][Full Text] [Related]
37. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
38. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic gene editing: delivery and regulatory perspectives.
Shim G; Kim D; Park GT; Jin H; Suh SK; Oh YK
Acta Pharmacol Sin; 2017 Jun; 38(6):738-753. PubMed ID: 28392568
[TBL] [Abstract][Full Text] [Related]
40. PEGylated Lipid bilayer coated mesoporous silica nanoparticles for co-delivery of paclitaxel and curcumin: Design, characterization and its cytotoxic effect.
Lin J; Cai Q; Tang Y; Xu Y; Wang Q; Li T; Xu H; Wang S; Fan K; Liu Z; Jin Y; Lin D
Int J Pharm; 2018 Jan; 536(1):272-282. PubMed ID: 29079221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]